NanoViricides (NNVC)
(Delayed Data from AMEX)
$1.13 USD
-0.07 (-5.83%)
Updated May 3, 2024 04:00 PM ET
After-Market: $1.12 -0.01 (-0.88%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
NanoViricides, Inc. [NNVC]
Reports for Purchase
Showing records 1 - 13 ( 13 total )
Company: NanoViricides, Inc.
Industry: Medical - Drugs
Company: NanoViricides, Inc.
Industry: Medical - Drugs
Company: NanoViricides, Inc.
Industry: Medical - Drugs
We are Initiating Coverage at rating with Buy
Provider: VEYO PARTNERS LLC
Company: NanoViricides, Inc.
Industry: Medical - Drugs
Company: NanoViricides, Inc.
Industry: Medical - Drugs
Company: NanoViricides, Inc.
Industry: Medical - Drugs
We initiate coverage with a price target of $7.21 per share.
Provider: SEETHRUEQUITY, LLC
Analyst: TANDON A
Company: NanoViricides, Inc.
Industry: Medical - Drugs
We initiate coverage with a price target of $7.21 per share.
Provider: SEETHRUEQUITY, LLC
Analyst: TANDON A
Company: NanoViricides, Inc.
Industry: Medical - Drugs
Suspension of Coverage: NNVC: Suspending Coverage of NanoViricides, Inc.
Provider: STONEGATE CAPITAL MARKETS
Analyst: ENGEL L
Company: NanoViricides, Inc.
Industry: Medical - Drugs
Research Update: NNVC: Q1FY12 Results and Pre IND Meeting Request Submitted
Provider: STONEGATE CAPITAL MARKETS
Analyst: ENGEL L
Company: NanoViricides, Inc.
Industry: Medical - Drugs
Company: NanoViricides, Inc.
Industry: Medical - Drugs
FluCide Selected as First Clinical Candidate for FDA Submission
Provider: STONEGATE CAPITAL MARKETS
Analyst: ENGEL L
Company: NanoViricides, Inc.
Industry: Medical - Drugs
Company: NanoViricides, Inc.
Industry: Unclassified
|